

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Vision impairment and differential use of eye health services by ethnicity in Aotearoa New Zealand: Protocol for a scoping review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048215
Article Type:	Protocol
Date Submitted by the Author:	23-Dec-2020
Complete List of Authors:	Rogers, Jaymie; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry & Vision Science Black, Joanna; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry and Vision Science Harwood, Matire; The University of Auckland School of Population Health, General Practice & Primary Health Care Wilkinson, Ben; Auckland District Health Board Ophthalmology Gordon, Iris; London School of Hygiene & Tropical Medicine, International Centre for Eye Health Ramke, Jacqueline; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry & Vision Science; London School of Hygiene & Tropical Medicine, International Centre for Eye Health
Keywords:	OPHTHALMOLOGY, Cataract and refractive surgery < OPHTHALMOLOGY, PUBLIC HEALTH, Glaucoma < OPHTHALMOLOGY, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Medical retina < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Vision impairment and differential use of eye health services by ethnicity in Aotearoa New Zealand: Protocol for a scoping review

Jaymie T Rogers,¹ Joanna Black,¹ Matire Harwood,² Ben Wilkinson,³ Iris Gordon⁴, Jacqueline Ramke^{1,4}

1. School of Optometry & Vision Science, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand
2. Department of General Practice & Primary Health Care, School of Population Health, University of Auckland, Auckland, New Zealand
3. Department of Ophthalmology, Auckland District Health Board, Auckland, New Zealand
4. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Corresponding author

Jaymie T Rogers

Postal address

School of Optometry and Vision Science, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Email j.rogers@auckland.ac.nz ORCID iD <http://orcid.org/0000-0003-2415-8198>

Author information

Jacqueline Ramke

Email j.ramke@auckland.ac.nz ORCID iD <http://orcid.org/0000-0002-5764-1306>

Joanna Black

Email j.black@auckland.ac.nz ORCID iD <http://orcid.org/0000-0002-5100-8796>

Matire Harwood

Email m.harwood@auckland.ac.nz ORCID iD <http://orcid.org/0000-0003-1240-5139>

Ben Wilkinson

Email bwilkinson.md@gmail.com ORCID iD <https://orcid.org/0000-0002-2629-7063>

Iris Gordon

Email Iris.Gordon@lshtm.ac.uk ORCID iD <http://orcid.org/0000-0001-8143-8132>

Word count 1617

Keywords

Vision impairment, vision screening, vision function, eye health, eye service, eye diseases, healthcare disparity, health equity, optometry, ophthalmology, Māori health, Pacific health, New Zealand

ABSTRACT

Introduction

In Aotearoa New Zealand, Māori and Pacific people experience worse health outcomes compared to other New Zealanders. No population-based eye health survey has been conducted, and eye health services do not generate routine monitoring reports, so the extent of eye health inequality is unknown. This information is required to plan equitable eye health services. Here we outline the protocol for a scoping review to report the nature and extent of the evidence reporting vision impairment, and the use of eye care services by ethnicity in New Zealand.

Methods and analysis

An information specialist will conduct searches on MEDLINE and Embase, with no limit on publication dates or language. We will search the grey literature via websites of relevant government and service provider agencies. Reference lists of included articles will be screened. Observational studies will be included if they report the prevalence of vision impairment, or any of the main causes (cataract, uncorrected refractive error, macular degeneration, glaucoma, or diabetic retinopathy), or report the use of eye care services in New Zealand among people of any age. Two authors will independently review titles, abstracts, and full text articles, and complete data extraction. Overall findings will be summarised using descriptive statistics and thematic analysis, with an emphasis on disaggregation by ethnicity where this information is available.

Ethics and dissemination

Ethical approval has not been sought as our review will only include published and publicly accessible data. We will publish the review in an open access peer reviewed journal. We anticipate the findings will be useful to organisations and providers in New Zealand responsible to plan and deliver eye care services, as well as stakeholders in other countries with differential access to eye care.

Registration details

The protocol has been registered with Open Science Framework: URL <https://osf.io/yw7xb>

Article summary

Strengths and limitations of this study

- The broad scope of this review will result in the first synthesis to date on the extent of the evidence on vision impairment, its main causes and use of eye care services across ethnicity groups in New Zealand.
- The search will be performed by an information specialist, and screening and data extraction will be performed in duplicate.
- We anticipate limited information on some causes of vision impairment, and inconsistent disaggregation of outcomes by ethnicity.

INTRODUCTION

Rationale

Globally, an estimated 43 million people were blind, and 295 million people had moderate or severe vision impairment in 2020.¹ In high-income countries, including Aotearoa New Zealand (hereafter referred to as New Zealand), the main causes of blindness and moderate or severe vision impairment (collectively referred to as vision impairment) are cataract, macular degeneration, glaucoma, uncorrected refractive error and diabetic retinopathy.² Most people with vision impairment are older adults, however diabetic retinopathy is the leading cause of vision impairment in the working age group.³ Diabetic retinopathy is projected to be an increasingly common cause of vision impairment in the coming decades due to the rising prevalence of diabetes.⁴

Although some countries are striving to reduce health inequalities,⁵ achieving equitable health outcomes is an intractable challenge.⁶ In many countries, people who are Indigenous, living with socioeconomic disadvantage and marginalised communities face barriers to accessing health care.⁷ Consequently, systemic and chronic health conditions are more prevalent among these people.⁸ They also tend to have higher rates of vision impairment.^{9, 10} For example, in Australia the prevalence of cataract is higher among Indigenous people, reflecting lower access to eye care compared to non-Indigenous Australians.^{7, 11}

Māori, the Indigenous people of New Zealand, are one of six main ethnicity groups (defined by Statistics New Zealand as “a cultural group a person identifies with or has a sense of belonging to”).¹² In the 2018 Census, 70% of New Zealanders identified with at least one European ethnicity, 17% identified as Māori, 8% identified with at least one Pacific peoples’ ethnicity, 15% identified as Asian, 2% identified as Middle Eastern/Latin American/African and 1% identified as other ethnicity.¹³

Inequities in health, and ethnic variations in the prevalence of systemic diseases has been reported in New Zealand.¹⁴ The health gap is persistent between Māori and non-Māori.¹⁵ Chronic conditions such as diabetes, cardiovascular disease and chronic obstructive pulmonary disease are more prevalent among Māori compared to other New Zealanders.^{16, 17} Māori also have a 25 fold need for renal replacement therapy¹⁴ and a 30% higher risk of developing a cardiovascular event compared to European New Zealanders.¹⁸

Inequities in eye health are well-documented in several high-income countries.^{11, 19, 20} In New Zealand the extent of inequity in eye health is largely unknown. New Zealand has never had a population-based eye health survey. A systematic review has been conducted on diabetic retinopathy prevalence and services,²¹ but synthesis of information on other causes of vision impairment has not been undertaken. This information would assist decision-makers to plan equitable eye health services.

The aim of this scoping review is to summarise the nature and extent of evidence in New Zealand on:

- 1) The distribution of vision impairment and its major causes by ethnicity; and
- 2) Differential access to eye health services by ethnicity.

As there is no New Zealand-specific information available on the main causes of vision impairment, we will assess the evidence on main causes in high-income countries.² We chose to undertake a scoping review rather than a systematic review, as we anticipate that the available evidence will be heterogenous.²²

METHODS AND ANALYSIS

Objectives/scoping review questions

We aim to answer the following questions:

- 1) What is the nature and extent of the available evidence on vision impairment in New Zealand?
- 2) What is the available evidence on the prevalence of the major causes of vision impairment in New Zealand?
- 3) How and in what ways is vision impairment and its major causes distributed across ethnicity groups?
- 4) What is the available evidence on differential access to eye health services for the major causes of vision impairment by ethnicity?

Protocol and registration

The protocol for this scoping review is reported according to the relevant items of the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist (supplementary annex 1).²³ The protocol has been registered with Open Science Framework: URL <https://osf.io/yw7xb>.

Patient and public involvement

There are no patient or public involvement as our review will only include published and publicly accessible data.

Eligibility criteria

We will include studies that meet the following criteria:

Types of studies

Observational study types such as cross sectional, case control and consecutive case series will be included. Non-consecutive cases series will be excluded. Research letters and grey literature, such as District Health Board (DHB) reports will be included, if they report data for at least one of our outcomes of interest. Editorials and conference abstracts will be excluded. We will have no time limit or language restrictions; a full text must be available.

Outcomes

Studies will be included if they report outcomes among residents of New Zealand (whether disaggregated by ethnicity or not), or attendees at New Zealand health facilities (regardless of size, public/private sector, or level of care). There will be no age restriction. Multi-country studies will be included if the results are reported separately for New Zealand.

We will include studies that report at least one of:

- the prevalence of vision impairment;
- the prevalence of cataract, uncorrected refractive error, macular degeneration, glaucoma or diabetic retinopathy;
- the prevalence of vision impairment due to cataract, uncorrected refractive error, macular degeneration, glaucoma or diabetic retinopathy;
- attendance at eye health service such as ophthalmology services, optometric services, and eye health screening programmes (e.g., diabetic retinopathy, preschool screening);
- rates of treatment for cataract, uncorrected refractive error, macular degeneration, glaucoma, or diabetic retinopathy.

We will include studies which report these outcomes by person. Studies which only report the outcomes by eye or by eye health service visit will be excluded.

Search

Published literature search

We will search MEDLINE and Embase using search strategies developed by a Cochrane Eyes and Vision Information Specialist (IG). Our MEDLINE search strategy is included in supplementary annex 2. We will examine reference lists of all included articles to identify further potentially relevant studies.

Grey literature search

We will include grey literature that report data for at least one of our outcomes. Using Google search engine, separate searches will be performed across:

- New Zealand government websites such as Ministry of Health and district health boards;
- Professional associations such as New Zealand Association of Optometry (NZAO) and the Royal Australian and New Zealand College of Ophthalmologists (RANZCO);
- Non-profit organisations and charitable trusts such as Blind Low Vision New Zealand and Macular Degeneration New Zealand.

General search terms will be used to identify eligible information within each website. Relevant links within documents to other sources of information will be pursued. A single reviewer will perform the search and identify eligible data, with verification from a second reviewer.

Search terms will include:

- “vision”, “eye”, “eye health”, “eye service”, “vision tests” and “vision screening”
- “cataract”, “uncorrected refractive error”, “macular degeneration”, “glaucoma” or “diabetic retinopathy”.

Study selection

Covidence systematic review software will be used for screening (Veritas Health Innovation, Melbourne, Australia. Available at: www.covidence.org). Two reviewers will independently screen the title and abstract of identified studies to exclude publications that clearly do not meet the inclusion criteria. The full text article will be retrieved for review if the citation seems potentially relevant. Any discrepancies between the reviewers will be resolved by discussion and a third reviewer will be consulted if necessary. A PRISMA flow diagram will be completed to summarise the study selection process.

Data charting process

A custom form will be developed in Excel for data charting. The form will be piloted on three studies and required amendments agreed by consensus. As we anticipate a broad scope of studies, the data charting process will be iterative, and the data charting form will be amended as required. Each included study will be charted independently by two reviewers. Any discrepancies between the reviewers will be resolved by discussion, and a third reviewer will be consulted if necessary. We plan to contact study authors in the case of unclear information and will make up to three attempts by email.

Data items

The following data items will be collected during the data charting process:

1. Source characteristics
 - a) Published data – Author(s), year of publication, title, journal, and study design.
 - b) Grey literature – Author (organisation e.g., Ministry of Health), year of publication, source website (e.g., government/non-government organisation), type of literature (report, thesis, technical report, statistic, other).
2. Study characteristics: Year(s) of data collection, sample size, age group of study population, demographics of study population such as gender and ethnicity. Geographic area (e.g., city, district) and study setting (e.g., facility level).
3. Outcomes as outlined above. We will extract all outcomes at the aggregate level, as well as disaggregated by ethnicity, gender, DHB, and area level deprivation wherever available.

Synthesis of results

We will summarise findings narratively and in tables. Information for each outcome will be disaggregated by cause of impairment, ethnicity, age, geographic region and area level deprivation where these are available.²⁴

Where possible, we will use Statistics New Zealand level 2 main categories for ethnicity (European, Māori, Pacific people, Asian and Middle Eastern/Latin American/African),¹² and otherwise report according to information provided by authors.

Where possible, we will use the ICD-11 categories of vision impairment, based on presenting visual acuity in the better eye. i.e. mild vision impairment is visual acuity of 6/12 or worse to 6/18 inclusive; moderate vision impairment is visual acuity worse than 6/18 to 6/60 inclusive; severe vision impairment is visual acuity worse than 6/60 to 3/60 inclusive and blindness is visual acuity worse than 3/60.²⁵

ETHICS AND DISSEMINATION

Ethical approval has not been sought as our review will only include published and publicly accessible data. We will publish the review in an open access peer reviewed journal. We anticipate the findings will be useful to organisations and providers in New Zealand responsible to plan and deliver eye care services, as well as stakeholders in other countries with differential access to eye care.

Authors' contributions

JTR drafted the protocol with suggestions from JR, JB, MH, IG and BW who reviewed the protocol and provided feedback on the draft. IG constructed the search. The final version of the protocol was approved by all authors.

Funding statement

Award/Grant number is not applicable. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. JTR is a recipient of the University of Auckland Senior Health Research Scholarship. JR's appointment at the University of Auckland is funded by the Buchanan Charitable Foundation, New Zealand.

Competing interests

None declared

Patient consent for publication

Not required

Licence statement

JTR is signing on behalf of all co-authors of the work

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

REFERENCES

1. Bourne R, Adelson J, Flaxman S, et al. Trends in Prevalence of Blindness and Distance and Near Vision Impairment Over 30 Years and Contribution to the Global Burden of Disease in 2020. *Lancet Glob Health [Preprint]*. 2020 [cited Dec 2020] <http://dx.doi.org/10.2139/ssrn.3582742>.
2. Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. *Br J Ophthalmol*. 2018;102:575-585.
3. Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. *Ophthalmol*. 2020;243:9-20.
4. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35:556-564.
5. Martin S, Siciliani L, Smith P. Socioeconomic inequalities in waiting times for primary care across ten OECD countries. *Soc Sci Med*. 2020;263.
6. Ministry of Health. *Achieving equity in health outcomes: highlights of important national and international papers*. Wellington, New Zealand: Ministry of Health; 2018.
7. Taylor HR, Xie J, Fox S, et al. The prevalence and causes of vision loss in Indigenous Australians: the National Indigenous Eye Health Survey. *Med J Aust*. 2010;192:312-318.
8. Gu Y, Warren J, Kennelly J, et al. Cardiovascular disease risk management for Māori in New Zealand general practice. *Journal of Primary Health Care*. 2014;6:286-294.
9. Foreman J, Keel S, van Wijngaarden P, et al. Prevalence and Causes of Visual Loss Among the Indigenous Peoples of the World: A Systematic Review. *JAMA ophthalmology*. 2018;136:567-580.
10. Foreman J, Xie J, Keel S, et al. The Prevalence and Causes of Vision Loss in Indigenous and Non-Indigenous Australians: The National Eye Health Survey. *American Academy of Ophthalmology*. 2017;124:1743-1752.
11. Kelaher M, Ferdinand A, Taylor H. Access to eye health services among indigenous Australians: an area level analysis. *BMC Ophthalmol*. 2012;12:51.
12. Stats NZ Tatauranga Aotearoa. 2018 Census ethnic groups dataset: <https://www.stats.govt.nz/information-releases/2018-census-ethnic-groups-dataset> [Accessed Dec 2020]
13. Stats NZ Tatauranga Aotearoa. 2018 Census data: <https://www.stats.govt.nz/tools/2018-census-place-summaries/new-zealand#ethnicity-culture-and-identity> [Accessed Dec 2020]
14. Atlantis E, Joshy G, Williams M, et al. Diabetes Among Māori and Other Ethnic Groups in New Zealand. *Diabetes Mellitus in Developing Countries and Underserved Communities*; 2017:165-190 DOI 110.1007/1978-1003-1319-41559-41558_41510 [Ebook].
15. Ferdinand A, Lambert M, Trad L, et al. Indigenous engagement in health: lessons from Brazil, Chile, Australia and New Zealand. *International journal for equity in health*. 2020;19:1-12.
16. Doughty R, Devlin G, Clinton J, et al. Health equity in the New Zealand health care system: a national survey. *International Journal for Equity in Health*. 2011;10:45.
17. Ellison - Loschmann L, Pearce N. Improving access to health care among New Zealand's Māori population. *American Journal of Public Health*. 2006;96:612-617.
18. Kenealy T, Elley CR, Robinson E, et al. An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. *Diabetic Medicine*. 2008;25:1302-1308.
19. Aljied R, Aubin MJ, Buhrmann R, et al. Prevalence and determinants of visual impairment in Canada: cross-sectional data from the Canadian Longitudinal Study on Aging. *Canadian Journal of Ophthalmology*. 2018;53:291-297.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Yip JLY, Luben R, Hayat S, et al. Area deprivation, individual socioeconomic status and low vision in the EPIC-Norfolk Eye Study. *J Epidemiol Community Health*. 2014;68:204-210.
 21. Ramke J, Jordan V, Vincent AL, et al. Diabetic eye disease and screening attendance by ethnicity in New Zealand: A systematic review. *Clin Exp Ophthalmol*. 2019;47:937-947.
 22. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. 2005;8:19-32.
 23. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation. *Ann Intern Med*. 2018;169:467-473.
 24. Atkinson J, Salmond C, Crampton P. *NZDep2013 Index of Deprivation*. Wellington: Department of Public Health, University of Otago, Wellington 2014 URL <https://www.otago.ac.nz/wellington/otago069936.pdf> [Accessed Dec 2020]
 25. WHO. *International Classification of disease 11 Vision impairment including blindness* 2018 URL <https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2fcd%2fentity%2f30317704> [Accessed Dec 2020]

Supplementary Annex 1: PRISMA-ScR Checklist

Section	Item	PRISMA-ScR checklist item	Reported on page #
Title			
Title	1	Identify the report as a scoping review.	1
Abstract			
Structured summary	2	Provide a structured summary including, as applicable: background, objectives, eligibility criteria, sources of evidence, charting methods, results and conclusions that relate to the review question(s) and objective(s).	1
Introduction			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review question(s)/objective(s) lend themselves to a scoping review approach.	3
Objectives	4	Provide an explicit statement of the question(s) and objective(s) being addressed with reference to their key elements (e.g., population or participants, concepts, and context), or other relevant key elements used to conceptualize the review question(s) and/or objective(s).	4
Methods			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify the characteristics of the sources of evidence (e.g., years considered, language, publication status) used as criteria for eligibility, and provide a rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with authors to identify additional sources) in the search, as well as the date the most recent search was executed.	5
Search	8	Present the full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5, Annex 1
Selection of sources of evidence	9	State the process for selecting sources of evidence (i.e., screening, eligibility) included in the scoping review.	5-6
Data charting process	10	Describe the methods of charting data from the included sources of evidence (e.g., piloted forms; forms that have been tested by the team before their use, whether data charting was done independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6
Critical appraisal of individual sources of evidence	12	If done provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	N/A
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	6

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* ;169:467–473. doi: 10.7326/M18-0850

Supplementary Annex 2: MEDLINE search terms

1. New Zealand/
2. Aotearoa.tw.
3. (New adj2 Zealand\$).tw.
4. (Auckland or Hamilton or Palmerston or Wellington or Nelson or Christchurch or Dunedin).tw.
5. (Maori or Maoris).tw.
6. (Pasifika or Pacifica).tw.
7. (Pacific adj2 (people\$ or patient\$ or island\$)).tw.
8. (Samoan or Tongan or Niuean).tw.
9. (Cook adj1 Island\$).tw.
10. Te Wai o Rona.tw.
11. or/1-10
12. exp Cataract/
13. cataract\$.tw.
14. exp Refractive Errors/
15. (myopia or myopic or myopes or hyperop\$ or hypermetrop\$ or presbyop\$).tw.
16. (refractive adj1 error\$).tw.
17. Eyeglasses/
18. (spectacle or spectacles).tw.
19. (eyeglasses or eye glasses).tw.
20. exp Visual Acuity/
21. (visual adj1 acuit\$).tw.
22. Retinal Degeneration/ or Macular Degeneration/ or Wet Macular Degeneration/
23. ((macul\$ or retina\$) adj2 degener\$).tw.
24. maculopathy.tw.
25. exp Glaucoma/
26. (glaucoma\$ or ocular hypertension).tw.
27. Diabetic Retinopathy/
28. ((diabet\$ or proliferat\$) adj3 retinopath\$).tw.
29. (diabet\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
30. (retinopath\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
31. (dilated adj2 fundus).tw.
32. (retinal adj2 exam\$).tw.
33. Blindness/
34. Vision, Low/
35. ((low\$ or impair\$ or partial\$ or loss\$ or limit\$) adj3 (vision or visual\$ or sight\$)).tw.
36. Vision Screening/
37. Vision Tests/
38. Visual Field Tests/
39. ((eye\$ or vision or retina\$ or ophthalm\$ or retinopathy) adj2 exam\$).tw.
40. ((eye\$ or vision or retinopathy or ophthalm\$) adj2 assess\$).tw.
41. ((eye\$ or vision or retina\$ or ophthalm\$ or retinopathy) adj2 test\$).tw.
42. (eye\$ adj2 (disease\$ or care or health or service\$)).tw.
43. or/12-42
44. 11 and 43
45. Prevalence/
46. prevalence.tw.
47. Health Surveys/
48. "Surveys and Questionnaires"/
49. (health adj2 (survey\$ or questionnaire\$)).tw.
50. exp Population Surveillance/
51. (population adj2 (base\$ or survey\$)).tw.
52. Mass Screening/
53. screen\$.tw.
54. "Quality of Health Care"/
55. Quality Improvement/
56. Delivery of Health Care/
57. National Health Programs/
58. State Medicine/
59. Regional Health Planning/
60. Health Planning/
61. Health Plan Implementation/
62. Health Planning Guidelines/
63. Health Care Reform/
64. Health Resources/
65. Health Priorities/
66. Health Services Research/
67. "health services needs and demand"/
68. Needs Assessment/
69. State Health Plans/
70. Regional Health Planning/
71. Community Health Planning/
72. Hospital Planning/
73. Regional Medical Programs/
74. Health Maintenance Organizations/
75. Comprehensive Health Care/
76. Health Facility Planning/
77. Health Facility Administration/
78. Hospital Administration/
79. exp Hospitals, public/
80. exp Hospitals, private/
81. health system\$.tw.
82. Models, Organizational/
83. Decision Making, Organizational/
84. Resource Allocation/
85. Efficiency, Organizational/
86. Organizational Innovation/
87. Delivery of Health Care, Integrated/
88. Interdisciplinary Communication/
89. Public Health/
90. Health Promotion/
91. Policy Making/
92. Program Development/
93. Program Evaluation/
94. Quality Control/
95. Quality Assurance, Health Care/
96. Benchmarking/
97. Capacity Building/
98. Health Services Accessibility/
99. Health Policy/
100. Surgical Procedures, Operative/
101. exp Surgical Equipment/
102. Health Care Rationing/
103. Medically Underserved Area/
104. exp Communication/

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

105. exp Culture/ ethnic\$).tw.
 106. Sex Factors/ 139. or/45-138
 107. Women's Rights/ 140. exp Eye Diseases/
 108. Prejudice/ 141. (eye\$ or ocular or vision).tw.
 109. Vulnerable Populations/ 142. Ophthalmology/
 110. Social Responsibility/ 143. optometry/ or orthoptics/
 111. Social Welfare/ 144. (Ophthalmologist\$ or Optometrist\$ or Optician\$ or
 112. Urban Health Services/ Orthoptist\$ or Refractionists).tw.
 113. Rural Health Services/ 145. (Ophthalmic adj3 (surgeon\$ or physician\$ or nurse\$
 114. Primary Prevention/ or technician\$ or officer\$ or assistant\$ or staff\$ or
 115. Preventive Health Services/ worker\$)).tw.
 116. Community Health Services/ 146. (eye\$ adj3 (surgeon\$ or physician\$ or nurse\$ or
 117. Community Health Nursing/ technician\$ or officer\$ or assistant\$ or staff\$ or
 118. Health Services, Indigenous/ worker\$)).tw.
 119. Rural Health Services/ 147. or/140-146
 120. Mobile Health Units/ 148. 11 and 139 and 147
 121. exp Patient Acceptance of health Care/ 149. 44 or 148
 122. exp Attitude to Health/ 150. (rabbit\$ or guinea or fish or rat or rats or mouse or
 123. exp Health Behavior/ mice or bird or birds or chicken).ti.
 124. Health Education/ 151. (New adj1 Zealand adj4 rabbit\$).tw.
 125. exp Patient Education as Topic/ 152. (Hamilton adj2 (depression or anxiety or rating)).tw.
 126. exp Health Promotion/ 153. (Nelson adj2 (staging or stage or grading or grade or
 127. Socioeconomic Factors/ classif\$ or Mandela or Lord or Admiral or
 128. exp Poverty/ Horatio)).tw.
 129. Social Class/ 154. (India or China or Ethiopia).ti.
 130. Employment/ 155. (cell or cells or apoptosis or vitro or vivo).ti.
 131. Healthcare Disparities/ 156.(gene or genes or genetic or polymorph\$).ti.
 132. Health Status Disparities/ 157. (mutation or molecular or chromosome or biopsy or
 133. Rural Population/ Zika).ti.
 134. Urban Population/ 158. or/150-157
 135. exp Ethnic Groups/ 159. 149 not 158
 136. Minority Groups/ 160. case reports/
 137. ((health\$ or social\$ or racial\$ or ethnic\$) adj5 161. 159 not 160
 (inequalit\$ or inequit\$ or disparit\$ or equit\$ or 162. limit 161 to (editorial or letter)
 disadvantage\$ or depriv\$)).tw. 163. 161 not 162
 138. (disadvant\$ or marginali\$ or underserved or under
 served or impoverish\$ or minorit\$ or racial\$ or

BMJ Open

Vision impairment and differential access to eye health services in Aotearoa New Zealand: Protocol for a scoping review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048215.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jul-2021
Complete List of Authors:	Rogers, Jaymie; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry & Vision Science Black, Joanna; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry and Vision Science Harwood, Matire; The University of Auckland School of Population Health, General Practice & Primary Health Care Wilkinson, Ben; Auckland District Health Board Ophthalmology Gordon, Iris; London School of Hygiene & Tropical Medicine, International Centre for Eye Health Ramke, Jacqueline; The University of Auckland Faculty of Medical and Health Sciences, School of Optometry & Vision Science; London School of Hygiene & Tropical Medicine, International Centre for Eye Health
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Health services research, Ophthalmology, Public health
Keywords:	OPHTHALMOLOGY, Cataract and refractive surgery < OPHTHALMOLOGY, Glaucoma < OPHTHALMOLOGY, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Medical retina < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Vision impairment and differential access to eye health services in Aotearoa New Zealand: Protocol for a scoping review

Jaymie T Rogers,¹ Joanna Black,¹ Matire Harwood,² Ben Wilkinson,³ Iris Gordon⁴, Jacqueline Ramke^{1,4}

1. School of Optometry & Vision Science, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand
2. Department of General Practice & Primary Health Care, School of Population Health, University of Auckland, Auckland, New Zealand
3. Department of Ophthalmology, Auckland District Health Board, Auckland, New Zealand
4. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Corresponding author

Jaymie T Rogers

Postal address

School of Optometry and Vision Science, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Email j.rogers@auckland.ac.nz ORCID iD <http://orcid.org/0000-0003-2415-8198>

Author information

Joanna Black

Email j.black@auckland.ac.nz ORCID iD <http://orcid.org/0000-0002-5100-8796>

Matire Harwood

Email m.harwood@auckland.ac.nz ORCID iD <http://orcid.org/0000-0003-1240-5139>

Ben Wilkinson

Email bwilkinson.md@gmail.com ORCID iD <https://orcid.org/0000-0002-2629-7063>

Iris Gordon

Email Iris.Gordon@lshtm.ac.uk ORCID iD <http://orcid.org/0000-0001-8143-8132>

Jacqueline Ramke

Email j.ramke@auckland.ac.nz ORCID iD <http://orcid.org/0000-0002-5764-1306>

Word count 1939

Keywords

Vision impairment, vision screening, vision function, eye health, eye service, eye diseases, healthcare disparity, health equity, optometry, ophthalmology, Māori health, Pacific health, New Zealand

ABSTRACT

Introduction

In Aotearoa New Zealand, Māori and Pacific people experience worse health outcomes compared to other New Zealanders. No population-based eye health survey has been conducted, and eye health services do not generate routine monitoring reports, so the extent of eye health inequality is unknown. This information is required to plan equitable eye health services. Here we outline the protocol for a scoping review to report the nature and extent of the evidence reporting vision impairment, and the use of eye health services by ethnicity in New Zealand.

Methods and analysis

An information specialist will conduct searches on MEDLINE and Embase, with no limit on publication dates or language. We will search the grey literature via websites of relevant government and service provider agencies. Reference lists of included articles will be screened. Observational studies will be included if they report the prevalence of vision impairment, or any of the main causes (cataract, uncorrected refractive error, macular degeneration, glaucoma, or diabetic retinopathy), or report the use of eye health services in New Zealand among people of any age. Two authors will independently review titles, abstracts, and full text articles, and complete data extraction. Overall findings will be summarised using descriptive statistics and thematic analysis, with an emphasis on disaggregation by ethnicity where this information is available.

Ethics and dissemination

Ethical approval has not been sought as our review will only include published and publicly accessible data. We will publish the review in an open access peer reviewed journal. We anticipate the findings will be useful to organisations and providers in New Zealand responsible to plan and deliver eye care services, as well as stakeholders in other countries with differential access to eye care.

Registration details

The protocol has been registered with Open Science Framework: URL <https://osf.io/yw7xb>

Article summary

Strengths and limitations of this study

- The broad scope of this review will result in the first synthesis to date on the extent of the evidence on vision impairment, its main causes and use of eye health services across ethnicity groups in New Zealand.
- The search will be performed by an information specialist, and screening and data extraction will be performed in duplicate.
- We anticipate limited information on some causes of vision impairment, and inconsistent disaggregation of outcomes by ethnicity.

INTRODUCTION

Rationale

The recent *Lancet Global Health Commission on Global Eye Health* defined eye health as “maximised vision, ocular health, and functional ability, thereby contributing to overall health and wellbeing, social inclusion, and quality of life”¹. Eye health services are then considered any service which contributes to this broad definition of eye health. The need for accessible eye health services is large and increasing. Globally, an estimated 43 million people were blind, and 295 million people had moderate or severe vision impairment in 2020². In high-income countries, including Aotearoa New Zealand (hereafter referred to as New Zealand), the main causes of blindness and moderate or severe vision impairment (collectively referred to as vision impairment) are cataract, macular degeneration, glaucoma, uncorrected refractive error and diabetic retinopathy³. Most people with vision impairment are older adults, however diabetic retinopathy is the leading cause of vision impairment in the working age group⁴. Diabetic retinopathy is projected to be an increasingly common cause of vision impairment in the coming decades due to the rising prevalence of diabetes⁵.

Although some countries are striving to reduce health inequalities⁶, achieving equitable health outcomes is an intractable challenge⁷. In many countries, people who are Indigenous, living with socioeconomic disadvantage and marginalised communities face barriers to accessing health care⁸. Consequently, systemic and chronic health conditions are more prevalent among these people⁹. They also tend to have higher rates of vision impairment^{10, 11}. For example, in Australia the prevalence of cataract is higher among Indigenous people, reflecting lower access to eye health services, compared to non-Indigenous Australians^{8, 12}.

Māori, the Indigenous people of New Zealand, are one of six main ethnicity groups (defined by Statistics New Zealand as “a cultural group a person identifies with or has a sense of belonging to”)¹³. In the 2018 Census, 70% of New Zealanders identified with at least one European ethnicity, 17% identified as Māori, 8% identified with at least one Pacific peoples’ ethnicity, 15% identified as Asian, 2% identified as Middle Eastern/Latin American/African and 1% identified as other ethnicity¹⁴.

Inequities in health, and ethnic variations in the prevalence of systemic diseases has been reported in New Zealand¹⁵. The health gap is persistent between Māori and non-Māori¹⁶. Chronic conditions such as diabetes, cardiovascular disease and chronic obstructive pulmonary disease are more prevalent among Māori compared to other New Zealanders^{17, 18}. Māori also have a 25 fold need for renal replacement therapy¹⁵ and a 30% higher risk of developing a cardiovascular event compared to European New Zealanders¹⁹. Inequities in health, and ethnic variations in the prevalence of systemic diseases has been reported in New Zealand¹⁵. The health gap is persistent between Māori and non-Māori¹⁶. Chronic conditions such as diabetes, cardiovascular disease and chronic obstructive pulmonary disease are more prevalent among Māori compared to other New Zealanders^{17, 18}. Māori also have a 25 fold need for renal replacement therapy¹⁵ and a 30% higher risk of developing a cardiovascular event compared to European New Zealanders¹⁹.

Inequities in eye health are well-documented in several high-income countries^{12, 20, 21}. In New Zealand the extent of inequity in eye health is largely unknown. New Zealand has never had a population-based eye health survey. A systematic review has been conducted on diabetic retinopathy prevalence and services²², but synthesis of information on other causes of vision impairment has not been undertaken. This information would assist decision-makers to plan equitable eye health services.

The aim of this scoping review is to summarise the nature and extent of evidence in New Zealand on:

- 1) The distribution of vision impairment and its major causes by ethnicity; and
- 2) Differential access to eye health services by ethnicity.

As there is no New Zealand-specific information available on the main causes of vision impairment, we will assess the evidence on main causes in high-income countries³. We chose to undertake a scoping review rather than a systematic review, as we anticipate that the available evidence will be heterogenous²³.

METHODS AND ANALYSIS

We will follow the methodological steps for scoping reviews outlined by Arksey and O'Malley²³. Our team includes researchers (JB, MH, JRa) with experience in conducting scoping reviews including on service delivery models to address inequities in eye health^{24, 25}.

Objectives/scoping review questions

To achieve our aim we will answer the following questions:

- 1) What is the nature and extent of the available evidence on vision impairment in New Zealand?
- 2) What is the available evidence on the prevalence of the major causes of vision impairment in New Zealand?
- 3) How and in what ways is vision impairment and its major causes distributed across ethnicity groups?
- 4) What is the available evidence on differential access to eye health services for the major causes of vision impairment by ethnicity?

Protocol and registration

The protocol for this scoping review is reported according to the relevant items of the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist (supplementary annex 1)²⁶. The protocol has been registered with Open Science Framework: URL <https://osf.io/yw7xb>.

Patient and public involvement

There are no patient or public involvement as our review will only include published and publicly accessible data.

Eligibility criteria

We will include studies that meet the following criteria:

Context

Studies will be included if they report outcomes among residents of New Zealand (whether disaggregated by ethnicity or not), or attendees at New Zealand health facilities (regardless of size, public/private sector, or level of care). Multi-country studies will be included if the results are reported separately for New Zealand.

Types of studies

Observational study types such as cross sectional, case control and consecutive case series will be included. Non-consecutive cases series will be excluded. Research letters and grey literature, such as District Health Board (DHB) reports will be included, if they report data for at least one of our outcomes of interest. Editorials and conference abstracts will be excluded. We will have no time limit or language restrictions. Only studies where the full article is available will be included. We will use the University of Auckland's comprehensive inter-library loan service to retrieve articles not readily available.

Participants

We will include studies of any population group resident in New Zealand. There will be no age or gender restriction.

Concept/Outcomes

We will include studies that report at least one of:

- the prevalence of vision impairment;
- the prevalence of cataract, uncorrected refractive error, macular degeneration, glaucoma or diabetic retinopathy;
- the prevalence of vision impairment due to cataract, uncorrected refractive error, macular degeneration, glaucoma or diabetic retinopathy;
- attendance at eye health service such as ophthalmology services, optometric services, and eye health screening programmes (e.g., diabetic retinal screening, children vision screening);
- rates of treatment for cataract, uncorrected refractive error, macular degeneration, glaucoma, or diabetic retinopathy.

We will include studies which report these outcomes by person. Studies which only report the outcomes by eye or by eye health service visit will be excluded.

Search

Published literature search

We will search MEDLINE and Embase using search strategies developed by a Cochrane Eyes and Vision Information Specialist (IG). Our search strategy used on MEDLINE is included in supplementary annex 2. We will apply a backward and forward snowball citation approach²⁷. We will examine reference lists of all included articles (backward) and also examine studies which have cited our included articles (forward) to identify potentially relevant studies.

Grey literature search

We will include grey literature that report data for at least one of our outcomes. General search terms will be used to identify eligible information within each website. Relevant links within documents to other sources of information will be pursued. A single reviewer will perform the search and identify eligible data, with verification from a second reviewer.

Using Google search engine, separate searches will be performed across:

- New Zealand government websites such as Ministry of Health and district health boards;
- Professional associations such as New Zealand Association of Optometry (NZAO) and the Royal Australian and New Zealand College of Ophthalmologists (RANZCO);

- Non-profit organisations and charitable trusts such as Blind Low Vision New Zealand and Macular Degeneration New Zealand.

We will limit our search to the first 20 items of Google search engines.

Google search terms will include:

- “vision”, “eye”, “eye health”, “eye service”, “vision tests” and “vision screening”
- “cataract”, “uncorrected refractive error”, “macular degeneration”, “glaucoma” or “diabetic retinopathy”.

In addition, field experts and key stakeholders will be contacted to share our list of included studies and request to identify further potentially relevant studies for consideration in the review.

Study selection

Covidence systematic review software will be used for screening (Veritas Health Innovation, Melbourne, Australia. Available at: www.covidence.org). Two reviewers will independently screen the title and abstract of identified studies to exclude publications that clearly do not meet the inclusion criteria. The full text article will be retrieved for review (via the University of Auckland library) if the citation seems potentially relevant. Any discrepancies between the reviewers will be resolved by discussion and a third reviewer will be consulted if necessary. A PRISMA flow diagram will be completed to summarise the study selection process.

Data charting process

A custom form will be developed in Excel for data charting. The form will be piloted on three studies and required amendments agreed by consensus. As we anticipate a broad scope of studies, the data charting process will be iterative, and the data charting form will be amended as required. Each included study will be charted independently by two reviewers. Any discrepancies between the reviewers will be resolved by discussion, and a third reviewer will be consulted if necessary. We plan to contact study authors in the case of unclear information and will make up to three attempts by email.

Data items

The following data items will be collected during the data charting process:

1. Source characteristics
 - a) Published data – Author(s), year of publication, title, journal, and study design.
 - b) Grey literature – Author (organisation e.g., Ministry of Health), year of publication, source website (e.g., government/non-government organisation), type of literature (report, thesis, technical report, statistic, other).
2. Study characteristics: Year(s) of data collection, sample size, age group of study population, demographics of study population such as gender and ethnicity. Geographic area (e.g., city, district) and study setting (e.g., facility level).
3. Outcomes as outlined above. We will extract all outcomes at the aggregate level, as well as disaggregated by ethnicity, gender, DHB, and area level deprivation wherever available.

Synthesis of results

We will summarise findings narratively and in tables. Information for each outcome will be disaggregated by cause of impairment, ethnicity, age, geographic region and area level deprivation where these are available²⁸.

1
2
3 Where possible, we will use Statistics New Zealand level 2 main categories for ethnicity (European,
4 Māori, Pacific people, Asian and Middle Eastern/Latin American/African),¹³ and otherwise report
5 according to information provided by authors.
6
7

8 Where possible, we will use the ICD-11 categories of vision impairment, based on presenting visual
9 acuity in the better eye. i.e. mild vision impairment is visual acuity of 6/12 or worse to 6/18 inclusive;
10 moderate vision impairment is visual acuity worse than 6/18 to 6/60 inclusive; severe vision
11 impairment is visual acuity worse than 6/60 to 3/60 inclusive and blindness is visual acuity worse than
12 3/60²⁹.
13
14

15
16 We will share our synthesis of the results with the field experts and key stakeholders engaged during
17 the search process, to get feedback on our summary of results²³.
18
19

20 21 **ETHICS AND DISSEMINATION**

22 Ethical approval has not been sought as our review will only include published and publicly accessible
23 data. We will publish the review in an open access peer reviewed journal. We anticipate the findings
24 will be useful to organisations and providers in New Zealand responsible to plan and deliver eye care
25 services, as well as stakeholders in other countries with differential access to eye care.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authors' contributions

JTR drafted the protocol with suggestions from JR, JB, MH, IG and BW who reviewed the protocol and provided feedback on the draft. IG constructed the search. The final version of the protocol was approved by all authors.

Funding statement

Award/Grant number is not applicable. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. JTR is a recipient of the University of Auckland Senior Health Research Scholarship. JR's appointment at the University of Auckland is funded by the Buchanan Charitable Foundation, New Zealand.

Competing interests

None declared

Patient consent for publication

Not required

Licence statement

JTR is signing on behalf of all co-authors of the work

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

REFERENCES

1. Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. *The Lancet Global Health*. 2021;9(4):e489-e551.
2. Bourne R, Adelson J, Flaxman S, et al. Trends in Prevalence of Blindness and Distance and Near Vision Impairment Over 30 Years and Contribution to the Global Burden of Disease in 2020. *Lancet Glob Health [Preprint]*. 2020 [cited Dec 2020] <http://dx.doi.org/10.2139/ssrn.3582742>.
3. Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. *Br J Ophthalmol*. 2018;102:575-585.
4. Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. *Ophthalmol*. 2020;243:9-20.
5. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35:556-564.
6. Martin S, Siciliani L, Smith P. Socioeconomic inequalities in waiting times for primary care across ten OECD countries. *Soc Sci Med*. 2020;263.
7. Ministry of Health. *Achieving equity in health outcomes: highlights of important national and international papers*. Wellington, New Zealand: Ministry of Health; 2018.
8. Taylor HR, Xie J, Fox S, et al. The prevalence and causes of vision loss in Indigenous Australians: the National Indigenous Eye Health Survey. *Med J Aust*. 2010;192:312-318.
9. Gu Y, Warren J, Kennelly J, et al. Cardiovascular disease risk management for Māori in New Zealand general practice. *Journal of Primary Health Care*. 2014;6:286-294.
10. Foreman J, Keel S, van Wijngaarden P, et al. Prevalence and Causes of Visual Loss Among the Indigenous Peoples of the World: A Systematic Review. *JAMA ophthalmology*. 2018;136:567-580.
11. Foreman J, Xie J, Keel S, et al. The Prevalence and Causes of Vision Loss in Indigenous and Non-Indigenous Australians: The National Eye Health Survey. *American Academy of Ophthalmology*. 2017;124:1743-1752.
12. Kelaher M, Ferdinand A, Taylor H. Access to eye health services among indigenous Australians: an area level analysis. *BMC Ophthalmol*. 2012;12:51.
13. Stats NZ Tauranga Aotearoa. 2018 Census ethnic groups dataset: <https://www.stats.govt.nz/information-releases/2018-census-ethnic-groups-dataset> [Accessed Dec 2020]
14. Stats NZ Tauranga Aotearoa. 2018 Census data: <https://www.stats.govt.nz/tools/2018-census-place-summaries/new-zealand#ethnicity-culture-and-identity> [Accessed Dec 2020]
15. Atlantis E, Joshy G, Williams M, et al. Diabetes Among Māori and Other Ethnic Groups in New Zealand. *Diabetes Mellitus in Developing Countries and Underserved Communities*; 2017:165-190 DOI 10.1007/1978-1003-1319-41559-41558_41510 [Ebook].
16. Ferdinand A, Lambert M, Trad L, et al. Indigenous engagement in health: lessons from Brazil, Chile, Australia and New Zealand. *International journal for equity in health*. 2020;19:1-12.
17. Doughty R, Devlin G, Clinton J, et al. Health equity in the New Zealand health care system: a national survey. *International Journal for Equity in Health*. 2011;10:45.
18. Ellison - Loschmann L, Pearce N. Improving access to health care among New Zealand's Māori population. *American Journal of Public Health*. 2006;96:612-617.
19. Kenealy T, Elley CR, Robinson E, et al. An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. *Diabetic Medicine*. 2008;25:1302-1308.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Aljied R, Aubin MJ, Buhrmann R, et al. Prevalence and determinants of visual impairment in Canada: cross-sectional data from the Canadian Longitudinal Study on Aging. *Canadian Journal of Ophthalmology*. 2018;53:291-297.
 21. Yip JLY, Luben R, Hayat S, et al. Area deprivation, individual socioeconomic status and low vision in the EPIC-Norfolk Eye Study. *J Epidemiol Community Health*. 2014;68:204-210.
 22. Ramke J, Jordan V, Vincent AL, et al. Diabetic eye disease and screening attendance by ethnicity in New Zealand: A systematic review. *Clin Exp Ophthalmol*. 2019;47:937-947.
 23. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. 2005;8:19-32.
 24. Burn H, Hamm L, Black J, et al. Eye care delivery models to improve access to eye care for Indigenous peoples in high-income countries: A scoping review. *BMJ Global Health*. 2021;6(3).
 25. Hamm LM, Black J, Burn H, et al. Interventions to promote access to eye care for non-Indigenous, non-dominant ethnic groups in high-income countries: a scoping review protocol. *BMJ Open*. 2020;10(6):e033775.
 26. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation. *Ann Intern Med*. 2018;169:467-473.
 27. Jalali S, Wohlin C. Systematic literature studies: Database searches vs. backward snowballing. Paper presented at: International Symposium on Empirical Software Engineering and Measurement, 2012.
 28. Atkinson J, Salmond C, Crampton P. *NZDep2013 Index of Deprivation*. Wellington: Department of Public Health, University of Otago, Wellington 2014 URL <https://www.otago.ac.nz/wellington/otago069936.pdf> [Accessed Dec 2020]
 29. WHO. *International Classification of disease 11 Vision impairment including blindness 2018* URL <https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2fcd%2fentity%2f30317704> [Accessed Dec 2020]

Supplementary Annex 1: PRISMA-ScR Checklist

Section	Item	PRISMA-ScR checklist item	Reported on page #
Title			
Title	1	Identify the report as a scoping review.	1
Abstract			
Structured summary	2	Provide a structured summary including, as applicable: background, objectives, eligibility criteria, sources of evidence, charting methods, results and conclusions that relate to the review question(s) and objective(s).	1
Introduction			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review question(s)/objective(s) lend themselves to a scoping review approach.	3
Objectives	4	Provide an explicit statement of the question(s) and objective(s) being addressed with reference to their key elements (e.g., population or participants, concepts, and context), or other relevant key elements used to conceptualize the review question(s) and/or objective(s).	4
Methods			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify the characteristics of the sources of evidence (e.g., years considered, language, publication status) used as criteria for eligibility, and provide a rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with authors to identify additional sources) in the search, as well as the date the most recent search was executed.	5
Search	8	Present the full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5, Annex 1
Selection of sources of evidence	9	State the process for selecting sources of evidence (i.e., screening, eligibility) included in the scoping review.	5-6
Data charting process	10	Describe the methods of charting data from the included sources of evidence (e.g., piloted forms; forms that have been tested by the team before their use, whether data charting was done independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6
Critical appraisal of individual sources of evidence	12	If done provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	N/A
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	6

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* ;169:467–473. doi: 10.7326/M18-0850

Supplementary Annex 2: MEDLINE search terms

1. New Zealand/
2. Aotearoa.tw.
3. (New adj2 Zealand\$).tw.
4. (Auckland or Hamilton or Palmerston or Wellington or Nelson or Christchurch or Dunedin).tw.
5. (Maori or Maoris).tw.
6. (Pasifika or Pacifica).tw.
7. (Pacific adj2 (people\$ or patient\$ or island\$)).tw.
8. (Samoan or Tongan or Niuean).tw.
9. (Cook adj1 Island\$).tw.
10. Te Wai o Rona.tw.
11. or/1-10
12. exp Cataract/
13. cataract\$.tw.
14. exp Refractive Errors/
15. (myopia or myopic or myopes or hyperop\$ or hypermetrop\$ or presbyop\$).tw.
16. (refractive adj1 error\$).tw.
17. Eyeglasses/
18. (spectacle or spectacles).tw.
19. (eyeglasses or eye glasses).tw.
20. exp Visual Acuity/
21. (visual adj1 acuit\$).tw.
22. Retinal Degeneration/ or Macular Degeneration/ or Wet Macular Degeneration/
23. ((macul\$ or retina\$) adj2 degener\$).tw.
24. maculopathy.tw.
25. exp Glaucoma/
26. (glaucoma\$ or ocular hypertension).tw.
27. Diabetic Retinopathy/
28. ((diabet\$ or proliferat\$) adj3 retinopath\$).tw.
29. (diabet\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
30. (retinopath\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
31. (dilated adj2 fundus).tw.
32. (retinal adj2 exam\$).tw.
33. Blindness/
34. Vision, Low/
35. ((low\$ or impair\$ or partial\$ or loss\$ or limit\$) adj3 (vision or visual\$ or sight\$)).tw.
36. Vision Screening/
37. Vision Tests/
38. Visual Field Tests/
39. ((eye\$ or vision or retina\$ or ophthalm\$ or retinopathy) adj2 exam\$).tw.
40. ((eye\$ or vision or retinopathy or ophthalm\$) adj2 assess\$).tw.
41. ((eye\$ or vision or retina\$ or ophthalm\$ or retinopathy) adj2 test\$).tw.
42. (eye\$ adj2 (disease\$ or care or health or service\$)).tw.
43. or/12-42
44. 11 and 43
45. Prevalence/
46. prevalence.tw.
47. Health Surveys/
48. "Surveys and Questionnaires"/
49. (health adj2 (survey\$ or questionnaire\$)).tw.
50. exp Population Surveillance/
51. (population adj2 (base\$ or survey\$)).tw.
52. Mass Screening/
53. screen\$.tw.
54. "Quality of Health Care"/
55. Quality Improvement/
56. Delivery of Health Care/
57. National Health Programs/
58. State Medicine/
59. Regional Health Planning/
60. Health Planning/
61. Health Plan Implementation/
62. Health Planning Guidelines/
63. Health Care Reform/
64. Health Resources/
65. Health Priorities/
66. Health Services Research/
67. "health services needs and demand"/
68. Needs Assessment/
69. State Health Plans/
70. Regional Health Planning/
71. Community Health Planning/
72. Hospital Planning/
73. Regional Medical Programs/
74. Health Maintenance Organizations/
75. Comprehensive Health Care/
76. Health Facility Planning/
77. Health Facility Administration/
78. Hospital Administration/
79. exp Hospitals, public/
80. exp Hospitals, private/
81. health system\$.tw.
82. Models, Organizational/
83. Decision Making, Organizational/
84. Resource Allocation/
85. Efficiency, Organizational/
86. Organizational Innovation/
87. Delivery of Health Care, Integrated/
88. Interdisciplinary Communication/
89. Public Health/
90. Health Promotion/
91. Policy Making/
92. Program Development/
93. Program Evaluation/
94. Quality Control/
95. Quality Assurance, Health Care/
96. Benchmarking/
97. Capacity Building/
98. Health Services Accessibility/
99. Health Policy/
100. Surgical Procedures, Operative/
101. exp Surgical Equipment/
102. Health Care Rationing/
103. Medically Underserved Area/
104. exp Communication/

- 1
2
3 105. exp Culture/ ethnic\$).tw.
4 106. Sex Factors/ 139. or/45-138
5 107. Women's Rights/ 140. exp Eye Diseases/
6 108. Prejudice/ 141. (eye\$ or ocular or vision).tw.
7 109. Vulnerable Populations/ 142. Ophthalmology/
8 110. Social Responsibility/ 143. optometry/ or orthoptics/
9 111. Social Welfare/ 144. (Ophthalmologist\$ or Optometrist\$ or Optician\$ or
10 112. Urban Health Services/ Orthoptist\$ or Refractionists).tw.
11 113. Rural Health Services/ 145. (Ophthalmic adj3 (surgeon\$ or physician\$ or nurse\$
12 114. Primary Prevention/ or technician\$ or officer\$ or assistant\$ or staff\$ or
13 115. Preventive Health Services/ worker\$)).tw.
14 116. Community Health Services/ 146. (eye\$ adj3 (surgeon\$ or physician\$ or nurse\$ or
15 117. Community Health Nursing/ technician\$ or officer\$ or assistant\$ or staff\$ or
16 118. Health Services, Indigenous/ worker\$)).tw.
17 119. Rural Health Services/ 147. or/140-146
18 120. Mobile Health Units/ 148. 11 and 139 and 147
19 121. exp Patient Acceptance of health Care/ 149. 44 or 148
20 122. exp Attitude to Health/ 150. (rabbit\$ or guinea or fish or rat or rats or mouse or
21 123. exp Health Behavior/ mice or bird or birds or chicken).ti.
22 124. Health Education/ 151. (New adj1 Zealand adj4 rabbit\$).tw.
23 125. exp Patient Education as Topic/ 152. (Hamilton adj2 (depression or anxiety or rating)).tw.
24 126. exp Health Promotion/ 153. (Nelson adj2 (staging or stage or grading or grade or
25 127. Socioeconomic Factors/ classif\$ or Mandela or Lord or Admiral or
26 128. exp Poverty/ Horatio)).tw.
27 129. Social Class/ 154. (India or China or Ethiopia).ti.
28 130. Employment/ 155. (cell or cells or apoptosis or vitro or vivo).ti.
29 131. Healthcare Disparities/ 156.(gene or genes or genetic or polymorph\$).ti.
30 132. Health Status Disparities/ 157. (mutation or molecular or chromosome or biopsy or
31 133. Rural Population/ Zika).ti.
32 134. Urban Population/ 158. or/150-157
33 135. exp Ethnic Groups/ 159. 149 not 158
34 136. Minority Groups/ 160. case reports/
35 137. ((health\$ or social\$ or racial\$ or ethnic\$) adj5 161. 159 not 160
36 (inequalit\$ or inequit\$ or disparit\$ or equit\$ or 162. limit 161 to (editorial or letter)
37 disadvantage\$ or depriv\$)).tw. 163. 161 not 162
38 138. (disadvant\$ or marginali\$ or underserved or under
39 served or impoverish\$ or minorit\$ or racial\$ or
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60